Lightnews — Scholar-powered news

Nuclear Medicine and Neurooncology (NMN)

@nmnsymposium.bsky.social

170 followers 130 following 97 posts

Advancing Nuclear Medicine and Neurooncology through research and education. Join the #NMN2025 Symposium on May 09/10th 2025 in Vienna, Austria. nmn-society.org

Posts Media Videos Starter Packs

Pinned

Nuclear Medicine and Neurooncology (NMN) @nmnsymposium.bsky.social · Apr 10

🚨 Apply now! The "NMN Clinical tRiaLisT Fellowship" offers training and hands-on experience in clinical trial development for theranostic treatments in CNS tumors: www.nmn-society.org/clinical-tri...!
@eanoassociation.bsky.social @neuroonc.bsky.social @eortc.org

1 3

Nuclear Medicine and Neurooncology (NMN) @nmnsymposium.bsky.social · 1d

💫 New publication in EJNMMI: "Revealing the hidden: A systematic review and meta-analysis of FAPI-based tracers imaging for brain metastatic lesions."
link.springer.com/article/10.1...

Nuclear Medicine and Neurooncology (NMN) @nmnsymposium.bsky.social · 15d

💫 Check out the new article in the inaugural issue of the new EANM Journal:
EANM insights on PET-based response assessment in neuro-oncology: things are moving forward!
doi.org/10.1016/j.ea...
@eanm.org

1 4

Reposted by Nuclear Medicine and Neurooncology (NMN)

European Association of Nuclear Medicine (EANM) @eanm.org · 15d

We’re thrilled to see so many high-quality submissions coming in for our journals! 🎉

Explore the latest publications and the editorials written by our EANM Board and Editors-in-Chief:

👉 The EANM Journal: sciencedirect.com/journal/the-...
👉 EANM Innovation: sciencedirect.com/journal/eanm...

1 2

Nuclear Medicine and Neurooncology (NMN) @nmnsymposium.bsky.social · 16d

🚨New paper in EJNMMI: [177Lu]Lu-DOTATATE for refractory meningiomas: factors associated with the therapeutic response and initial tumor dosimetric data.
link.springer.com/article/10.1...

[177Lu]Lu-DOTATATE for refractory meningiomas: factors associated with the therapeutic response and initial tumor dosimetric data - European Journal of Nuclear Medicine and Molecular Imaging

Purpose This study aimed to reveal the factors affecting the therapeutic response of refractory meningiomas treated with [177Lu]Lu-DOTATATE and to collect initial tumor absorbed doses. Methods Patient...

link.springer.com

Reposted by Nuclear Medicine and Neurooncology (NMN)

The Society for Neuro-Oncology (SNO) @neuroonc.bsky.social · Sep 5

Who’s ready for 2025 WFNOS/SNO Annual meeting in Honolulu?!

Register by Sept 19 to get early bird pricing and join colleagues from around the world in advancing #neurooncology.

soc-neuro-onc.org/SNO2025

2 3

Nuclear Medicine and Neurooncology (NMN) @nmnsymposium.bsky.social · 21d

🧠 EANS-EANO Guidelines on the extent of resection in gliomas.
academic.oup.com/neuro-oncolo...

@eanoassociation.bsky.social @neuroonc.bsky.social

EANS-EANO Guidelines on the extent of resection in gliomas

Abstract. Intense efforts are employed to optimize neurosurgical resection of gliomas in different clinical scenarios. However, the level of evidence emplo

academic.oup.com

1 2

Nuclear Medicine and Neurooncology (NMN) @nmnsymposium.bsky.social · 25d

🚨 💫 Happy to share that that @eortc.org is a 🙌 collaboration partner for the #NMN2026 Symposium: www.nmn-society.org!
@nathaliealbert.bsky.social

1 1

Nuclear Medicine and Neurooncology (NMN) @nmnsymposium.bsky.social · 26d

🚨 New publication in Journal of Nuclear Medicine: Retrospective Evaluation of the Correlation Between Somatostatin Receptor PET/CT and Histopathology in Patients with Suspected Intracranial Meningiomas.
jnm.snmjournals.org/content/earl...

Retrospective Evaluation of the Correlation Between Somatostatin Receptor PET/CT and Histopathology in Patients with Suspected Intracranial Meningiomas

The aim of this retrospective study was to evaluate the correlation between findings from somatostatin receptor (SSTR) PET/CT and histopathology in patients with suspected intracranial meningiomas. Me...

jnm.snmjournals.org

1 2

Nuclear Medicine and Neurooncology (NMN) @nmnsymposium.bsky.social · 27d

🌎 ☢️ 🩺 Implementation of Radiotheranostics: Challenges, Barriers, and IAEA-Driven Strategies for Sustainable Access.
www.sciencedirect.com/science/arti...

Implementation of Radiotheranostics: Challenges, Barriers, and IAEA-Driven Strategies for Sustainable Access

Radiotheranostics represent a cutting-edge advancement in the management of noncommunicable diseases, integrating diagnostic imaging with targeted rad…

www.sciencedirect.com

Nuclear Medicine and Neurooncology (NMN) @nmnsymposium.bsky.social · 27d

New publication in Nature Reviews Clinical Oncology: The molecular blueprint of targeted radionuclide therapy.
www.nature.com/articles/s41...

The molecular blueprint of targeted radionuclide therapy - Nature Reviews Clinical Oncology

Targeted radionuclide therapy (TRT) is a therapeutic modality that combines the strengths of radiotherapy and systemic molecularly targeted therapy. Over the past few years, new TRT agents have been d...

www.nature.com

Nuclear Medicine and Neurooncology (NMN) @nmnsymposium.bsky.social · 29d

Prognostic value of [18F]FET-PET in diffuse low-grade (grade 2) gliomas after the 2021 classification of CNS tumors.
link.springer.com/article/10.1...

Prognostic value of [18F]FET-PET in diffuse low-grade (grade 2) gliomas after the 2021 classification of CNS tumors - European Journal of Nuclear Medicine and Molecular Imaging

Purpose Amino acid PET with [18F]-fluoroethylthyrosine ([18F]FET-PET) is frequently utilized in gliomas. Most studies on prognostication based on amino acid PET comprise mixed cohorts of brain tumors ...

link.springer.com

2 4

Nuclear Medicine and Neurooncology (NMN) @nmnsymposium.bsky.social · 29d

Assessment of 18F-FET PET-based response in patients with gliomas using the PET RANO 1.0 criteria.
academic.oup.com/noa/advance-...

Assessment of 18F-FET PET-based response in patients with gliomas using the PET RANO 1.0 criteria

AbstractBackground. We evaluated the amino acid PET-based response assessment criteria (PET RANO 1.0) for their proficiency in predicting longer survival i

academic.oup.com

1 3

Reposted by Nuclear Medicine and Neurooncology (NMN)

Winkler Laboratory @winklerlab.bsky.social · 29d

🚨 Registration deadline for the EACR conference on #cancerneuroscience is September 15 ‼️

Please join us in beautiful Bilbao for exciting discussions on the dialogue between the nervous system and cancer 🔬🧠

See you soon!

Introduction | Cancer Neuroscience | The European Association for Cancer Research

eacr.org

4 10

Nuclear Medicine and Neurooncology (NMN) @nmnsymposium.bsky.social · Sep 9

Tumor Versus Capillary Telangiectasia in Recurring Glioblastoma.
journals.lww.com/nuclearmed/f...
@nathaliealbert.bsky.social

Tumor Versus Capillary Telangiectasia in Recurring... : Clinical Nuclear Medicine

stant tumor manifestation. However, multimodal MRI revealed a benign capillary telangiectasia in the anterior cingulate gyrus. While 18F-FET-PET is highly sensitive for detecting tumor activity, vascu...

journals.lww.com

2 4

Reposted by Nuclear Medicine and Neurooncology (NMN)

EANO @eanoassociation.bsky.social · Sep 5

Thank you! We're pleased to support the #NMN2026 Symposium and collaborate with colleagues across the global neuro-oncology community. 🌐🧠 #EANO #Collaboration #NeuroOncology

1 1

Nuclear Medicine and Neurooncology (NMN) @nmnsymposium.bsky.social · Sep 5

Prediction of progression-free and overall survival following temozolomide chemoradiation using FET PET-based parameters including radiomics in patients with glioblastoma.
academic.oup.com/noa/advance-...

Prediction of progression-free and overall survival following temozolomide chemoradiation using FET PET-based parameters including radiomics in patients with glioblastoma

AbstractBackground. Early after surgery and completion of first-line radiotherapy with concomitant temozolomide, the prediction of progression-free and ove

academic.oup.com

1 5

Nuclear Medicine and Neurooncology (NMN) @nmnsymposium.bsky.social · Sep 1

🤩 Happy to share that the EANO is endorsing the #NMN2026 Symposium: www.nmn-society.org! 💫 Excited to join forces with the leading mulitdisciplinary neuro-oncology society in Europe 🌎 !
www.eano.eu
@eanoassociation.bsky.social @nathaliealbert.bsky.social @michael-platten.bsky.social

1 1

Nuclear Medicine and Neurooncology (NMN) @nmnsymposium.bsky.social · Aug 28

Spatial tumour characteristics as an indirect marker of metabolic dysregulation: evaluation for non-invasive IDH-genotyping of glioma using hybrid [18 F]FET-PET/MRI.
link.springer.com/article/10.1...

Spatial tumour characteristics as an indirect marker of metabolic dysregulation: evaluation for non-invasive IDH-genotyping of glioma using hybrid [18 F]FET-PET/MRI - European Journal of Nuclear Medic...

Purpose The isocitrate dehydrogenase (IDH) genotype is crucial for diagnosing and managing adult-type diffuse glioma. We investigated spatial tumour characteristics in treatment-naïve glioma using an ...

link.springer.com

1 2

Reposted by Nuclear Medicine and Neurooncology (NMN)

Nature Cancer @natcancer.nature.com · Aug 27

⭐️New Article published at Nature Cancer!

'Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling'

✒️By Wies Vallentgoed and colleagues

🔗 www.nature.com/articles/s43...

Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling - Nature Cancer

Vallentgoed et al. integrate clinical and multiomic data from persons with matched initial and recurrent IDH-mutant astrocytomas to identify progression-associated mechanisms and report a DNA methylat...

www.nature.com

3 7

Nuclear Medicine and Neurooncology (NMN) @nmnsymposium.bsky.social · Aug 27

Convection-enhanced delivery of [225Ac]Ac-DOTA-SP in recurrent glioblastoma – tumour uptake.
link.springer.com/article/10.1...

Convection-enhanced delivery of [225Ac]Ac-DOTA-SP in recurrent glioblastoma – tumour uptake - European Journal of Nuclear Medicine and Molecular Imaging

European Journal of Nuclear Medicine and Molecular Imaging -

link.springer.com

1 3

Nuclear Medicine and Neurooncology (NMN) @nmnsymposium.bsky.social · Aug 26

🔥 Hot off the press in Neuro-Oncology by @mj-mair.bsky.social et al: Prognostic stratification of newly diagnosed IDH-mutant gliomas by [18F]fluoroethyltyrosine and [11C]methionine PET – a retrospective, bicentric cohort study.
academic.oup.com/neuro-oncolo...

@eanoassociation.bsky.social

1 2

Nuclear Medicine and Neurooncology (NMN) @nmnsymposium.bsky.social · Aug 25

Early seizure freedom with [18F]fluorodopa positron emission tomography response after isocitrate dehydrogenase inhibition with vorasidenib: First case report.
onlinelibrary.wiley.com/doi/full/10....

Early seizure freedom with [18F]fluorodopa positron emission tomography response after isocitrate dehydrogenase inhibition with vorasidenib: First case report

Vorasidenib, a dual isocitrate dehydrogenase 1/2 (IDH1/2) inhibitor, showed superior efficacy in prolonging progression-free survival and time to next intervention in IDH-mutant grade 2 gliomas. This...

onlinelibrary.wiley.com

1 2

Nuclear Medicine and Neurooncology (NMN) @nmnsymposium.bsky.social · Aug 25

The role of amino acid PET in the era of checkpoint inhibitors and targeted therapy for brain tumor treatment.
journals.lww.com/co-neurology...

The role of amino acid PET in the era of checkpoint... : Current Opinion in Neurology

journals.lww.com

1 1

Reposted by Nuclear Medicine and Neurooncology (NMN)

EANO @eanoassociation.bsky.social · Aug 23

🧠 Just published in Neuro-Oncology: A comprehensive consensus review by @neuroonc.bsky.social and EANO on current management and future directions in adult #Glioblastoma care. Explore key recommendations and research priorities.
🔗 academic.oup.com/neuro-oncolo...

#NeuroOncology

1 5 10